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Background: The field of telehealth and telemedicine is expanding as the need to improve
efficiency of health care becomes more pressing. The decision to implement a telehealth
system is generally an expensive undertaking that impacts a large number of patients and
other  stakeholders. It is therefore extremely important that the decision is fully supported
by  accurate evaluation of telehealth interventions.
Objective: Numerous reviews of telehealth have described the evidence base as inconsistent.
In  response they call for larger, more rigorously controlled trials, and trials which go beyond
evaluation of clinical effectiveness alone. The aim of this paper is to discuss various ways
in  which evaluation of telehealth could be improved by the use of adaptive trial designs.
Results: We discuss various adaptive design options, such as sample size reviews and chang-
ing  the study hypothesis to address uncertain parameters, group sequential trials and
multi-arm multi-stage trials to improve efficiency, and enrichment designs to maximise
the  chances of obtaining clear evidence about the telehealth intervention.
Conclusion: There is potential to address the flaws discussed in the telehealth literature
through the adoption of adaptive approaches to trial design. Such designs could lead toimprovements in efficiency, allow the evaluation of multiple telehealth interventions in a
cost-effective way, or accurately assess a range of endpoints that are important in the overall
success of a telehealth programme.
© 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
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design stage of the study, so that if these changes do need.  Introduction
elehealth is the use of technology to allow communication
f information between patient and care-provider whilst the
atient is outside the clinical environment, e.g. in their own
ome. The range of telehealth is broad, from the monitoring
f blood glucose levels in diabetics who provide measure-
ents from home, to patients of mental illness receiving
herapy treatment online. It can allow low-cost monitoring of
he patient’s condition, which reduces demands on hospital
esources and staff. Implementation of an effective telehealth
ntervention therefore has the potential to lead to improved
atient care and improved efficiency in health care, which
as been demonstrated in various studies [1–4]. However,
idespread implementation of telehealth faces barriers due
o a lack of strong, valid evidence of its benefits. This lack of
vidence is discussed in Ekeland et al’s systematic review of
eviews, which examined up to 80 telehealth reviews in two
eparate papers [5,6]. According to their findings, telehealth
iterature suffers from several flaws. Firstly, many  of the trials
arried out are too small, lacking the power to find a benefit
ver standard care. Second, a lack of consistency in endpoints
n the literature makes it difficult to consolidate evidence.
urther, there is a belief that clinical effectiveness alone is
ot sufficient evidence for implementing a telehealth system.
ome reviews call for studies to include technical, ethical and
rganisational effects, including direct and indirect costs to
atients and care-providers. Lastly, several reviews discuss the
eterogeneity that can exist in patient responses to the same
elehealth intervention, contributing to inconsistency in the
vidence base. There is a lack of knowledge about why some
eople respond or comply well with a telehealth programme
ut others do not. Suggested explanations can be as objective
s the patient’s specific type of illness, or as subjective as thepatient’s personal sense of motivation. Reviews recommend
exploring reasons for varying response and compliance if the
telehealth intervention is to be successful.
It may be possible to address the criticisms and issues
discussed in reviews of telehealth through appropriate trial
design. Ekeland et al. [6] discuss methodology used in
telehealth studies, and recommend standard randomised
controlled trials as the most rigorous option of trial design.
In this paper we  argue that the evaluation of telehealth inter-
ventions could benefit from expanding this usual approach
to include adaptive trial designs. The potential advantages of
adaptive designs in drug trials have been examined in sev-
eral places in the literature [7,8]. The aim of this paper is to
introduce adaptive designs in the context of telehealth, tak-
ing into account the specific challenges that may arise when
evaluating telehealth interventions.
2.  Adaptive  designs
An adaptive design is one in which new decisions can be
made about the design or progress of the trial, once the trial
is already underway. This is in contrast to standard, non-
adaptive designs, in which all aspects of the trial are fixed
beforehand and remain fixed throughout. The changes made
in an adaptive trial are based on interim analyses of the
data observed so far. Examples of changes that may be made
are: stopping the trial early if efficacy or futility has already
been demonstrated; changing the endpoint or objective of the
study, and; re-estimating the sample size. Potential changes
are usually considered beforehand and incorporated into theto be made, any increase in resources required is known in
advance. At the end of the trial, the final analysis includes all
patients recruited since the beginning of the trial. Thus the
872  i n t e r n a t i o n a l j o u r n a l o f m e d i c a l i n f o r m a t i c s 8 3 ( 2 0 1 4 ) 870–880
Table 1 – Results of literature search for use of adaptive designs in telehealth studies.
No. of results
(total = 156)
Level of searcha Relevant/irrelevantb Reason(s) for relevance/irrelevance
144 Abstracts examined Irrelevant Any of the following: - Observational study
− Standard clinical trial (non-adaptive)
− Description of telehealth system but no evaluation
- Studies using electronic health records, not a
genuine telehealth intervention
8 Full text examined Irrelevant Interim analysis performed but not with the aim of
making changes to study, so not adaptive.
2 Full text examined Irrelevant Adaptive treatment strategies used, but only at the
patient level, such that a change in strategy does not
affect the overall design of the study [10,11]
1 Full text examined Irrelevant Adaptive design used but intervention was not
genuine telehealth [12]
1 Full text examined Irrelevant Adaptive randomisation used, but in terms of
covariates only, at beginning of trial - not in terms of
outcome [13]
a PubMed search terms: (telehealth OR telecare OR telehomecare OR telemedicine OR e-health OR ehealth) AND (adaptive OR interim OR
sequential).b With respect to the use of adaptive designs.
patients observed in the early stages contribute to optimising
the remainder of the trial, as well as to the final analysis. Adap-
tive designs have the potential to improve efficiency, power,
flexibility and ethical value of a trial. So far, however, the
potential of adaptive designs in telehealth studies has not
been explored. We  confirmed this by performing a literature
search, the results of which can be seen in Table 1. Search
terms for telehealth were chosen based on the range of ter-
minology discussed in a recent review [9], and the remaining
search terms were words likely to be used when describing
methodology of an adaptive design. Of 156 results returned,
most were found to be irrelevant upon reading their abstracts.
Of the rest, some used adaptive designs but the intervention
was not considered a genuine telehealth system, while oth-
ers studied genuine telehealth systems and made changes
at some point in the trial, but the changes did not affect
the overall study design and were not considered adaptive in
the strictest sense. The literature search, therefore, revealed a
research gap for adaptive designs in the context of telehealth.
In the remainder of this paper, we  will review the issues
that can arise in telehealth trials and suggest how adaptive
designs could be used to address those issues. Generally, our
suggestions are made in the context of improving randomised
controlled telehealth trials. Single-arm intervention trials are
typically only suitable when substantial information is avail-
able on outcomes in individuals without the intervention.
However, if such a scenario existed for a telehealth interven-
tion, then many  of the following adaptive designs could still be
applied in a single-arm study. Similarly, adaptive designs may
be useful for observational studies or other types of experi-
ment.
3.  Uncertain  parametersWhen planning a standard, fixed-sample randomised con-
trolled trial, the parameters used to compute the required
sample size include the desired power and type I error rateand the value of the intervention effect that would be clinically
relevant (the clinically relevant effect, CRE). Also required is a
measure of uncertainty in the outcome, which will be different
depending on the type of outcome being evaluated. For exam-
ple, for continuous outcomes the standard deviation of the
outcome is required, for binary outcomes it is the probability of
success without the intervention, or for survival outcomes it is
the event rate. In a telehealth trial, the CRE and the uncertainty
in the outcome can be difficult to estimate in advance. They
may be difficult to obtain due to the expense of running a pilot
telehealth trial. Further, in a drug trial, clinicians may be able
to refer to previous, similar trials to help form an estimate of
the parameters in their data. For telehealth, however, similar
studies rarely exist and it is difficult to estimate the potential
impact a telehealth system may have. Telehealth interven-
tions can be complex and the underlying mechanisms which
lead to successful outcomes may not be as well understood as
the physiological mechanisms that contribute to successful
drug treatments. Misspecification of parameters in a sample
size calculation will result in a sample size that is under- or
over-estimated. This will lead to inefficient scenarios in which
there are too few patients and so not enough power to detect
the desired intervention effect, or too many  patients, which
is unnecessarily expensive. There are several options of adap-
tive design in which an interim analysis takes place after some
data has been observed. This allows the previously estimated
parameters to be adjusted according to the new information.
3.1.  Sample  size  review
A sample size review allows the opportunity to recalculate the
sample size at an interim stage of the study, either at a pre-
specified time, or after a pre-specified number of patients has
been observed. Interim data, i.e. the data collected so far, is
used to estimate the parameters of the data and these are
used in a new sample size calculation. Subsequent recruit-
ment plans are adjusted to reflect the new sample size, and
a l i n
s
V
p
t
i
w
p
3
T
c
w
c
i
s
a
o
I
t
fi
c
p
a
s
t
i
v
e
e
o
s
c
4
A
c
o
s
a
c
o
i
r
b
b
b
a
o
e
4
C
a
i
l
I
that trials are conducted in the best interest of the patient, i.e.
ethically. As in drug studies, it would be unethical to continuei n t e r n a t i o n a l j o u r n a l o f m e d i  c 
o the trial achieves the desired power and type I error rate.
arious methods of sample size re-estimation exist, including
rocedures to avoid unblinding and procedures using condi-
ional power. Gould [14] discusses these methods, along with
ssues involved in sample size re-estimation and situations in
hich they may not be suitable, for example if the recruitment
rocess is particularly complex.
.2.  Changing  the  clinically  relevant  effect
he CRE is the effect that the trial is powered to detect. In some
ases it represents the size of the intervention effect which
ould be important enough to make an impact in the clini-
al setting. In other cases any improvement at all may be of
nterest. The CRE is specified in advance in order to compute a
ample size. Due to the difficulty of anticipating the impact of
 telehealth system, the effect of the telehealth intervention
bserved at the interim may be far from what was expected.
n this case there would be little point in continuing with the
rial as it was originally planned, as the trial was powered to
nd a different effect. Instead, a more  realistic CRE should be
hosen. Then a sample size review may be carried out, incor-
orating this new value. The remaining recruitment would be
djusted to achieve the new sample size. Subsequent analy-
is of the study may need to be adapted in order to deal with
he possible effects of observing the intervention effect at the
nterim, such as an inflated type I error rate and biased inter-
ention effect. Such effects are discussed in a paper by Hung
t al. [15], which centres on the situation where the treatment
ffect observed at an interim stage is far off target in terms
f the original estimate. They discuss several ways in which
tatistical inference may be adjusted following a change in the
linically relevant effect.
.  Multiple  endpoints
 complex telehealth system may involve several interacting
omponents and is likely to impact on more  than one aspect
f health care. For example, the Whole Systems Demonstrator
tudy [16] is a large randomised controlled trial to investigate
 telehealth device for monitoring symptoms of patients with
hronic diseases and offering them advice to manage their
wn health. The study aims to evaluate various endpoints,
ncluding health service utilisation, cost of care, symptom
eduction, quality of life and well-being of the patient, and
urden on care-provider. In such a range of endpoints it may
e difficult to choose the primary endpoint of interest. If it
ecame apparent in a study, that the intervention was not
ffecting the primary endpoint, but was having a greater effect
n a secondary endpoint, it may be desirable to change the
ndpoint of interest entirely.
.1.  Changing  the  endpoint  of  interest
hanging the endpoint, i.e. changing the study hypothesis, at
n interim stage of the study carries some risk. Observing the
ntervention effect at this stage can introduce bias into the
ater results of the study, multiple testing may inflate the type
 error and the flexibility of being able to change the endpoint f o r m a t i c s 8 3 ( 2 0 1 4 ) 870–880 873
means failing trials could be manipulated into becoming suc-
cessful [17]. However, with careful planning and design these
risks may be minimised. Changing the hypothesis has the
potential to gain more  meaningful data about the interven-
tion being studied, rather than continuing the study with the
same endpoint, which may be wasteful and non-informative.
Several procedures to handle bias and control of type I error
rate are discussed in a paper by Hommel [18].
Alternatively, the study may plan to assess more  than one
endpoint from the beginning. Previous reviews recommend
that telehealth trials look at the impact of telehealth on a
broad range of areas. Therefore, a well-designed telehealth
trial will almost certainly involve multiple endpoints. When
conducting a trial that assesses multiple endpoints of equal
importance, it is important to control the type I error rate
whilst testing multiple hypotheses.
5.  Cluster  randomisation
Cluster randomisation is sometimes chosen for evaluating
telehealth, such as in the Whole Systems Demonstrator study
[16]. This is because often the telehealth intervention involves
implementing an entire system of changes, and this is much
easier to do across a whole health unit rather than attempting
to expose particular individuals. Adaptive methods will have
to take into account characteristics of clusters, such as within-
and between-cluster variability and randomness in cluster
size.
5.1.  Sample  size  review  for  cluster  randomised  trials
Lake et al. propose methodology to allow a sample size review
to take place in a cluster randomised trial [19]. Planning the
sample size for a cluster randomised trial requires reliable
estimates of within- and between-cluster variability and vari-
ability in cluster size. These estimates are difficult to estimate
in advance as it is unlikely that previous studies will exist that
examined the same clusters. A solution to this is to conduct
a sample size review at the interim, as discussed in a previ-
ous section. Lake et al’s approach is particularly suited to trials
where the cluster sizes are small, e.g. family units, and where
recruitment will take place over an extended length of time.
The telehealth setting is more  likely to have larger sizes of
clusters, e.g. GP practices. Extra consideration may need to be
given to whether a multi-stage study would be appropriate in
this case.
6.  Efficiency  and  ethics
Efficiency is important in telehealth trials because of the cost
involved in evaluating a telehealth system. It is also importantwith a treatment that is having adverse effects, or to deny con-
trol participants a treatment that was showing a clear benefit.
Several design options are available that are ethical and aim
to increase efficiency.
i c a l 874  i n t e r n a t i o n a l j o u r n a l o f m e d 
6.1.  Group  sequential  design
A group sequential design includes one or more  interim anal-
yses which offer the opportunity of stopping the trial early,
either because the intervention has already been shown to
work (stopping for efficacy), or because the evidence suggests
the intervention does not work (stopping for futility). Stop-
ping rules are derived for each interim, in which a test statistic
beyond a specified level means there is already significant evi-
dence of an effect and recruitment to the study does not need
to continue. Likewise, if the effect is negative and falls below a
specified threshold then there is significant evidence that the
intervention does not work and the trial must stop. Otherwise,
the trial continues until the next interim, in which the deci-
sion will be made again using more  data. The main advantage
of such a trial is that the expected sample size is generally
smaller and so is less costly on average. It is also, arguably,
the more  ethical option, because if the intervention is unsuc-
cessful then fewer patients have been exposed to it, and if the
intervention is successful, then the trial ends sooner and the
patients on standard treatment can be switched to the supe-
rior treatment. The stopping rules are essentially boundaries
with which the observed intervention effect is compared at
each interim analysis. Research into various types of stopping
rule has been on-going for many  years. Stopping rules and
general methodology of group sequential trials are thoroughly
explored in books by Jennison and Turnball and by Whitehead
[20,21]. Examples of common designs are illustrated in Fig. 1,
in which the boundaries indicate where interim test statistics
must fall in order for the study to be stopped with sufficient
evidence. Panel A of Fig. 1 shows a design by O’Brien and Flem-
ing [22]. Its shape has the advantage of allowing early stopping
when initial results are extreme. Panel B of Fig. 1 shows the
triangular design by Whitehead and Stratton [23]. The shape
of this design is suited for studies in which it is not expected
that the trial will stop for futility, but rather it is more  impor-
tant to allow stopping for efficacy. This may be suitable for
evaluating telehealth interventions in which causing harm is
not reasonably expected. Such an intervention could be one in
which the telehealth programme involves additional monitor-
ing on top of usual care. For a more  experimental telehealth
programme that replaces usual care, a group sequential design
would need to allow for the intervention being harmful, and
thus have suitable futility boundaries.
More  recently, Wason et al. [24] showed that efficiency of
multi-stage trials could be further enhanced. Their paper aims
to minimise the maximum expected sample size of the overall
study.
6.2.  Multi-arm  multi-stage  design
The complex nature of telehealth interventions means that
there could be many  design or implementation possibilities.
It may be useful to evaluate several versions of a telehealth
intervention at the same time. In fact, this could be more  use-
ful than a comparison between a single telehealth programme
and usual care as it may already be fair to anticipate that a
telehealth programme that involves extra patient monitoring
will lead to better outcomes than usual care. It is sensible,
then, to search for the best telehealth programme among ai n f o r m a t i c s 8 3 ( 2 0 1 4 ) 870–880
number of options. An adaptive trial that is suitable for this
situation is a multi-arm, multi-stage trial. The multi-arm fea-
ture means that patients are allocated to a control group or one
of a number of interventions. Compared to carrying out sepa-
rate two-arm trials to evaluate each intervention, this has the
advantage of increased efficiency as only one control group is
required. The multiple stages allow interim analyses to take
place, after which decisions can be made on how the study
should proceed. These decisions could be: (1) to drop arms
for futility, or stop early for efficacy if an effective treatment is
found, as in group sequential designs; (2) to drop the interven-
tion that is performing the worst; a so-called drop-the-loser
design, or; (3) change the allocation ratio for randomisation
so that more  patients are allocated to the best performing
interventions, known as adaptive randomisation. These three
approaches are discussed further in an article by Wason [8].
In the case of the telehealth intervention being expensive
compared to the control, further savings could be made by
changing the allocation ratio such that a higher proportion of
patients is recruited to the control group, compared to each of
the telehealth intervention groups. This may be done whilst
maintaining the level of statistical power [25].
6.3.  Seamless  phase  II/III  designs
Drug treatments go through several stages of development,
known as phases. After evaluating safety in a small phase
I study, a trial is carried out to see if the drug is effective
(phase II), often by evaluating a short-term endpoint related
to survival. This is followed by a larger trial to confirm effi-
cacy (phase III). Phase III trials are generally more  expensive
than phase II and so there should be reasonable evidence
from phase II before the drug progresses to phase III. Each
trial is independent, i.e. it does not use the data observed in
the previous trial. It would be more  efficient to make use of
the data collected in the early stages, in later trials. A seam-
less phase II/III design aims to carry out one uninterrupted
study that incorporates the exploratory aspects of a phase II
trial and the confirmatory aspects of a phase III trial [26]. The
study would contain a planned interim analysis where a deci-
sion is made as to whether the treatment should continue
into the next stage of the study, or, if multiple treatments
are being studied, which treatment should progress further.
In other words, results observed during the phase II stage can
be used to shape the design of the phase III stage. Although
telehealth technology does not have the formal development
process that drug treatments have, the principles of a seam-
less phase II/III design could be applied in relevant contexts to
add efficiency to the evaluation of telehealth. For example, if
we liken pilot studies and subsequent, substantive telehealth
studies to phases II and III, then it becomes clear to see that the
same approach could explore the potential of several options
of telehealth programme in the beginning of a trial, and then
take the most promising programme forward for the remain-
der of the trial, following an interim analysis. This has the
advantage of requiring fewer patients and taking less time
than two separate trials. This is very similar to the multi-
arm multi-stage design discussed in the previous section, in
which decisions can be made about several interventions at
the interim.
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Fig. 1 – Examples of stopping rule designs for group sequential trials. The dashed lines show the boundaries of the
stopping rules. If the test statistic in each interim analysis falls within the boundaries, the study proceeds to the next
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.  Compliance  and  usability
eviews on telehealth often recommend studying compliance
o and usability of telehealth programmes, reasoning that the
uccess of the telehealth intervention is just as dependent on
hese factors as on clinical benefit [27]. Non-compliance may
rise if the telehealth programme is too demanding or time-
onsuming [28]. It may also arise because of poor usability. For
xample, Johnston et al. [29] point out that an intervention
hat relies on the computer literacy of the user may not be
uitable for groups such as the elderly, who are less likely to
ave these skills.
Evaluating clinical outcomes of telehealth whilst not being
ware of the compliance rate among the patients may lead to
 biased estimate of the intervention effect. Non-compliance
ould also reduce the power of the study, as there are less peo-
le representing the intervention group. Adaptive approaches
o trial design may help address these issues whilst at the
ame time evaluating effectiveness for clinical outcomes.
.1.  Multi-arm  multi-stage,  or  seamless  phase  II/II
esigns
hese designs could be useful for telehealth systems for which
here is uncertainty about how well patients will adhere to
he intervention. Several versions of the intervention may be
valuated in the first stage of the trial, in terms of patient
ompliance. The best performing interventions may be taken
orward to the next stage, where their clinical efficacy is eval-
ated. The rationale is that there is little point in trying to
valuate clinical efficacy if the patients are not complying
ith the intervention, perhaps because of usability issues or trial is stopped.
because it is too demanding. To our knowledge, no one has
yet considered a trial design which incorporates both non-
compliance, in an exploratory stage, and clinical efficacy in
later stages. A trial that achieves this may be particularly
useful for evaluating telehealth and should be researched fur-
ther.
8.  Heterogeneity  among  responses  to
telehealth
Another issue discussed in the telehealth literature is that
of heterogeneity of the intervention effect, across subgroups
of patients. Reviews reported a lack of knowledge about why
patients can respond differently to the same intervention.
Sometimes this is a compliance issue. For example Azar et al.
[30] discuss how the success of a telemonitoring programme
in diabetics was partly dependent on the personal motivation
of the participants to adhere to the programme requirements.
The subjective nature of this heterogeneity could be difficult
to address. In other trials, however, the source of the het-
erogeneity may be less subjective. For example, Bewick et al.
[31] showed that web-based interventions designed to reduce
alcohol consumption had varying effect sizes depending on
the level of alcohol consumption at baseline. Some interven-
tions only became effective beyond a certain level of alcohol
use. Gathering information on which subgroups will experi-
ence a treatment benefit is useful for both running a trial
and implementing the system in practice. In a trial, including
participants in whom the intervention is not likely to work
weakens the effect to be evaluated. Instead, trials could target
the subgroup of patients in whom the intervention is likely
to work. Trials which do this are called enrichment trials, as
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Fig. 2 – Visual representation of adaptive enrichment design. Following the first stage of the study, the figure shows three
possible scenarios that may be observed in the results of the interim analysis, and will dictate how the study progresses.the recruitment is designed to enhance the chances of finding
a significant intervention effect. Enrichment trials are risky
when information on which subgroups are likely to respond
well is unreliable. For example, it may be that the interven-
tion works in a larger than anticipated group of patients. To
address this problem, an adaptive enrichment trial may be
more  suitable.
8.1.  Adaptive  enrichment  design
An adaptive enrichment trial aims to gain information about
which patients respond well in the initial stage of the trial,
and then uses this information during the recruitment for the
later stage of the trial [32]. At an interim analysis, the adaptive
enrichment trial may change the inclusion/exclusion criteria
of its participants. The first stage of the trial will require the
collection of information that is potentially useful in indicat-
ing the probability of success of the intervention. In drug trials,
this usually involves the measurement of biomarkers related
to the effects of the drug. In telehealth trials, a problem may
lie in deciding which variables should be measured, i.e. decid-
ing which variables are potentially predictive of a successful
response to the intervention. Fig. 2 illustrates the concept of an
adaptive enrichment design. It is based on a scenario in which
prior to the study it is suspected that a particular biomarker
will be associated with response to the intervention. We will
define the participants as “biomarker-positive” or “biomarker-
negative”, but designs in the continuous biomarker case are
also possible. Initial recruitment to the study is open to all
participants. After a follow-up period an interim analysis takesplace, in which the response to the intervention is compared
in the two groups of participants. If there is an indication
that the intervention works in all patients, the trial contin-
ues to recruit all patients. Otherwise, recruitment may be
restricted to one of the subgroups, or the trial may be termi-
nated for futility. These scenarios are numbered one to three
in Fig. 2. The figure demonstrates when the study continues
with the same recruitment strategy (scenario 1), when it con-
tinues with restricted recruitment (scenario 2) and when it
must be stopped due to a lack of success (scenario 3). We
can relate Fig. 2 back to Bewick et al’s alcohol use study
described earlier [31]. An adaptive enrichment approach to
their trial may have revealed the difference in successful
intervention between those with high alcohol consumption
and those with low alcohol consumption. The remainder of
the study could then have focussed on the more  responsive
subgroup, to obtain evidence for the intervention more  effi-
ciently.
The importance of targeting appropriate patients was
discussed in a qualitative study of the Whole System Demon-
strator trial. The Whole Systems Demonstrator trial evaluated
a telehealth service for chronic disease sufferers, enabling
them to take measurements of their symptoms, which would
be monitored remotely by healthcare staff. The qualitative
study, by Sanders et al. [33], conducted interviews with indi-
viduals who had declined to participate in the Whole System
Demonstrator study, or who had withdrawn after the study
began. Sanders et al. revealed several common reasons for
non-participation in those interviewed, including: belief that
they would have difficulty using the technology; negatively
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ssociating telehealth with a lack of independence; the feel-
ng that the frequent use of the telehealth service would
ake their illness seem too present in their lives; not wanting
o interfere with existing services, which they felt comfort-
ble with, and; the pressure of having to take their own
easurements every day. Anticipating non-participation for
hese reasons, in the same way we  have described in the
daptive enrichment design in Fig. 1, may not be possible
nless there are baseline covariates that are suitably predic-
ive. Nonetheless the presence of such patients in a study is
mportant as it may skew the effect of telehealth on clinical
utcomes. If enrichment designs could not be applied, sev-
ral versions of a telehealth system could be evaluated in
he first stage of a multi-arm multi-stage trial, as described
n the previous section on compliance. Whatever is most
uccessful in terms of compliance or satisfaction may be
aken forward for further study, to examine its clinical ben-
fits.
.  Monitoring  data  to  predict  adverse
vents
ne innovative type of telehealth involves frequent and regu-
ar monitoring of patient symptoms, with the aim of predicting
n adverse event in that patient. For example, the system
ould be designed to measure a continuous variable and if the
ariable crosses a pre-specified threshold then this indicates
n increased likelihood of an adverse event. The measure-
ent could also be a risk score, computed via the combination
f several variables. In either case, once the monitored data
ndicates high risk of an adverse event, care-providers will
espond to the patient. For example, the telehealth system in
he Whole Systems Demonstrator study contains an alert sys-
em of several levels, which indicates to the healthcare staff
hat action they should take to deal with the reported symp-
oms. The purpose of such systems is usually to reduce the
umber of hospital admissions that may result when adverse
vents are not dealt with immediately. Deciding when alerts
hould be made may be difficult. Having too high a threshold
ay miss patients who genuinely require attention, whereas
oo low a threshold could result in saturating the health care
ervices with patients whose needs were not urgent. The alert
ystem could be seen as a kind of diagnostic test, aiming to
dentify people who  require admission to hospital. In this
ase, the aim of a trial would be to assess whether the sys-
em correctly identified patients who  required an admission
o hospital.
.1.  Group  sequential  designs  for  diagnostic  tests
hese trials are the same as the group sequential trials
escribed in an earlier section. One or more  interim analy-
es take place to allow the opportunity to stop early if there
s already evidence to demonstrate an effect or lack of effect.
ith diagnostic tests, the intervention effect to be tested will
e related to the sensitivity and specificity of the prediction
ystem, e.g. area under the ROC curve (AUROC). Methodology
or this case is demonstrated in a paper by Mazumdar and Liu
34]. f o r m a t i c s 8 3 ( 2 0 1 4 ) 870–880 877
It may be the case that the outcome being predicted by
the telehealth device is prevented through appropriate action
taken by healthcare providers. In this situation, it would not
be possible to determine whether the patient would have defi-
nitely experienced that outcome. Without being able to define
the true status of the patient, measures of specificity and
sensitivity cannot be computed and so diagnostic methods
are irrelevant. Instead, a trial may look at the impact of the
prognostic telehealth device on healthcare utilisation, such as
number of hospital admissions. Group sequential trials may
still be applied, where at each interim the decision can be
made as to whether there is evidence for a clinically relevant
difference in hospital admissions between the telehealth and
control arms.
9.2.  Adaptive  enrichment  design
As evaluation of telehealth technology can be expensive,
it may not be cost-effective in a study regarding adverse
events to include participants who are very unlikely to expe-
rience such an event. An adaptive enrichment study may
be useful to discover the high-risk individuals and use this
information to restrict the inclusion criteria to the high-risk
individuals for the remainder of the trial. The same meth-
ods discussed in the previous section may be applied in this
context.
10.  Discussion
We  have discussed ways in which adaptive designs have
the potential to increase the accuracy and efficiency of tele-
health trials. Adopting these approaches may strengthen
the evidence to justify implementation of a telehealth sys-
tem. Benefits over a standard, non-adaptive trial include:
better estimation of the parameters required to adequately
power the study; flexibility to change the study hypothesis
if the impact from telehealth is not as expected; increased
efficiency due to the option of stopping early if sufficient
evidence has been obtained, and; the ability to evaluate sev-
eral interventions at once and choose which ones should
be studied further. More  accurate evaluation could avoid
inconsistencies across trials, as in some of the current liter-
ature.
We  have described characteristics of telehealth which
make it a promising area for utilising adaptive designs.
Firstly, the complexity of telehealth interventions and their
interaction with multiple endpoints calls for a non-standard
approach. Secondly, multiple elements of the telehealth pro-
gramme,  along with varying conditions between health care
sites, means that there may be more  than one option for
how telehealth is implemented, in terms of staff roles,
organisation of data monitoring and adjustments to exist-
ing care procedures. In a telehealth edition of the Health
Service Journal supplement, the Department of Health dis-
cusses the necessity of an overall service re-design alongside
the addition of telehealth [35]. Adaptive, multi-arm trials
could help choose between implementation options. Thirdly,
anticipating the impact of a telehealth system may be diffi-
cult. Feedback during a trial could lead to the desire to make
i c a l 
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changes, which would be problematic if the study protocol did
not make provisions for changes. This was an issue in the
Whole System Demonstrator trial, after which an organisa-
tional analysis discussed the frustration of gaining important
knowledge about service integration throughout the trial but
not being able to take action until the trial was completed
[36]. Use of adaptive designs could allow flexibility to make
changes to the trial, provided that the possibility of changes
was thoroughly considered at the design stage. Lastly, the
quality of existing telehealth studies in the literature has
been called into question in several recent reviews. Adaptive
designs offer efficient ways to obtain evidence more  rigor-
ously.
However, there will be some types of telehealth inter-
vention which have characteristics unsuited to an adaptive
design. For example, if long-term endpoints are of inter-
est, and there is no short-term endpoint that is informative,
then adaptive designs that try to achieve a lower expected
sample size will do little to add efficiency. This is because
such a trial offers the opportunity to stop early and avoid
further recruitment to the trial. But by the time a long-
term endpoint is observed, the majority of the planned
sample size is likely to have been recruited already and
so there is little opportunity to make changes in the
interim. There are non-adaptive methods we  have dis-
cussed, such as a multi-arm trial without multiple stages,
which may still add efficiency over a standard parallel group
design.
In all of the design options described in this paper, special
considerations may need to be given to particular character-
istics of telehealth studies. For example, a group sequential
design could be chosen in order to provide the opportu-
nity of stopping early, but it is likely that the telehealth
intervention will involve other factors to be addressed, such
as patient compliance, multiple endpoints or cluster ran-
domisation. Consequently, the best approach could be a
combination of several types of design described in this paper.
This may require methodological adjustments of the single
approaches.
The main challenge in using adaptive trials for the evalu-
ation of telehealth interventions is the added complexity to
the design and analysis process. One example is the stringent
need to maintain the type I error rate. This could act as a deter-
rent to proponents of telehealth who are not confident with
the statistical methodology. The potential advantages, how-
ever, are evident when considering the criticisms of previous
trials. The fact that so many  reviews have commented on the
lack of consistent evidence justifies a more  rigorous approach
being considered, regardless of its complexity. Further, regu-
lators look favourably on the merits of adaptive designs, and
the Food and Drug Administration (FDA) have prepared spe-
cific guidelines to assist researchers in planning such studies
[37]. Even so, a necessary aspect of choosing adaptive designs
over more  standard designs will be the inclusion of a statisti-
cal expert alongside the investigators. Furthermore, members
of review boards and data monitoring committees will need
to have sufficient knowledge of the adaptive design being
used in order to make informed decisions on the ethics of
the study. This is out of the hands of the investigator; we can
only hope that continued education and discussion such asi n f o r m a t i c s 8 3 ( 2 0 1 4 ) 870–880
in this paper will increase the awareness of adaptive designs
among members of research committees. Provided that review
board members consist of members who are acquainted with
the methodology, the monitoring of an adaptive design will
often be more  straightforward compared to a standard trial.
This is because potential changes to the trial - for example,
sample size recalculations, changes in recruitment criteria -
will have been incorporated into the design stage of the study
and will have pre-specified decision rules. When the trial is
approved, the potential changes are also approved, such that
if it is decided that the changes should be carried out at the
interim, these modifications do not need to be sent for review
again. Of course, this will be true only for the changes that have
been pre-specified. It may be the case that unforeseen modi-
fications are required, as in a standard, non-adaptive study.
The FDA is also positive regarding Bayesian approaches to
evaluation of interventions. Although they have not been dis-
cussed in this paper, Bayesian methods have the advantage
of incorporating prior knowledge into the design and anal-
ysis of trials. As discussed, such prior knowledge is often
absent for telehealth technologies, but there could still be
a place for Bayesian approaches in the adaptive designs we
have described, as they accumulate information throughout
the study. For many  of our suggested designs, the addition of
Bayesian features has been proposed in the literature and so
there is potential to explore the use of Bayesian methods in
telehealth studies.
11.  Conclusion
Previous methodological approaches to the evaluation of
telehealth interventions have contributed to inconsistent evi-
dence in the literature. We  suggest approaching telehealth
trial design with an adaptive framework. Although this will
likely involve further research into modifying current drug-
based trial designs, the added flexibility of adaptive trials has
the potential to produce more  accurate and efficient studies,
with clearer evidence to support decisions for implementa-
tion.
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Summary points
What was already known on this topic:
• Telehealth programmes have the potential to add effi-
ciency to the provision of healthcare and improve
patient outcomes through increased monitoring of
symptoms and self-management of health.
• Supporting the implementation of telehealth inter-
ventions on a large scale is difficult due to inconsistent
evidence across studies.
What this study added to our knowledge:
• No investigator of telehealth has yet carried out an
adaptive trial design for the evaluation of a telehealth
intervention.
• Adaptive trial designs such as sample size re-
estimation, group sequential designs, adaptive enrich-
ment designs, and multi-arm multi-stage designs, may
be useful in telehealth trials.
• Adaptive designs could improve the efficiency, cost-
effectiveness, accuracy and flexibility of telehealth
trials.
• Characteristics of telehealth interventions, such as
their impact on a range of endpoints, the lack of prior
information about a new telehealth programme, and
the heterogeneity in patient response, make them
rsuitable for an adaptive approach to evaluation.
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